MDGL Madrigal Pharmaceuticals, Inc.

396.74USD-0.34%Mkt Cap: 9.22B USDP/E: —

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directe…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap9.22B USD
Enterprise Value8.61B USD
Revenue (TTM)1.43B USD
Gross Profit902.25M USD
Net Income (TTM)-288.28M USD
Revenue/Share61.86 USD
Last Price396.74 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees915
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)38.22
PEG—
EV/EBITDA-56.98
EV/Revenue6.03
P/S6.45
P/B14.70
EPS (TTM)-5.85 USD
EPS (Forward)10.38 USD
52W Range
353.5417% of range615.00
52W High615.00 USD
52W Low353.54 USD
Profitability
Gross Margin94.14%
Oper. Margin-10.69%
EBITDA Margin-10.58%
Profit Margin-30.08%
ROE-47.83%
ROA-22.89%
ROIC—
ROCE-31.61%
Growth
Revenue Growth50.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-189.55M USD
CapEx (TTM)3.47M USD
FCF Margin-7.87%
FCF Yield-1.22%
Net Debt-606.75M USD
Net Debt/EBITDA4.02
Net Debt/FCF—
Balance Sheet
Debt/Equity0.58
Current Ratio3.05
Quick Ratio2.62
Book Value/Sh27.00 USD
Cash/Share41.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 25, 2016
Splits
Last Split1:35
Split DateJul 25, 2016
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)688.78 USD
Upside (mean)+73.6%
Target Range479.00 USD – 962.00 USD
479.00+73.6% to mean962.00
# Analysts18
Ownership
Shares Out.23.23M
Float15.80M
Insiders5.79%
Institutions98.56%
Short Interest
Short Ratio7.3d
Short % Float10.80%
Short % Out.9.20%
Shares Short2.14M
Short (prev mo.)2.40M
Technical
SMA 50468.17 (-15.3%)
SMA 200494.91 (-19.8%)
Beta-1.00
S&P 52W Chg12.00%
Avg Vol (30d)518.74K
Avg Vol (10d)559.83K
Technical Indicators
RSI (14)31.1
MACD-14.8724
MACD Signal-15.6190
MACD Hist.+0.7467
BB Upper452.89 USD
BB Middle421.24 USD
BB Lower389.59 USD
BB Width15.03%
ATR (14)21.06 USD
Vol Ratio (20d)0.69x

About Madrigal Pharmaceuticals (NASDAQ: MDGL)

›

Madrigal Pharmaceuticals (NASDAQ: MDGL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 915 employees.

The shares were at 396.74 USD on 19 November 2026, down 18.8% over 52 weeks. Its 52-week range is 353.54 USD to 615.00 USD: the price is 35.5% below the high and 12.2% above the low.

Its market capitalisation is 9.22B USD.

Madrigal Pharmaceuticals reports return on equity of -47.8%, an operating margin of -10.7% and revenue up 50.1% year over year.

It holds more cash than debt, a net cash position of 606.75M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 18 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 688.78 USD is 73.6% above the current price. The next earnings report is expected on 18 February 2027.